<HashMap><database>biostudies-literature</database><scores/><additional><omics_type>Unknown</omics_type><volume>15</volume><submitter>Guo S</submitter><pubmed_abstract>&lt;h4>Background&lt;/h4>Chimeric antigen receptor T cell (CAR-T) therapy for relapsed/refractory (r/r) B cell acute lymphoblastic leukemia (B-ALL) and B cell non-Hodgkin lymphoma (B-NHL) patients has shown promising effects, but side effects such as viral infections have been observed.&lt;h4>Methods&lt;/h4>A total of 45 patients with r/r B-ALL and r/r B-NHL were included in this retrospective study. Patient demographics were recorded, with the primary endpoint being viral infection within 3 months post CAR-T treatment. Univariate and multivariate logistic regression analyses and least absolute shrinkage and selection operator (LASSO) regression analysis were used to analyze independent factors. The patients were divided into a training cohort of 28 and a validation cohort of 17 to construct a predict</pubmed_abstract><journal>Frontiers in oncology</journal><pagination>1549809</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC11968754</full_dataset_link><repository>biostudies-literature</repository><pubmed_title>A viral infection prediction model for patients with r/r B-cell malignancies after CAR-T therapy: a retrospective analysis.</pubmed_title><pmcid>PMC11968754</pmcid><pubmed_authors>Liu J</pubmed_authors><pubmed_authors>Zhao M</pubmed_authors><pubmed_authors>Cao X</pubmed_authors><pubmed_authors>Wang B</pubmed_authors><pubmed_authors>Zhang X</pubmed_authors><pubmed_authors>Xiao X</pubmed_authors><pubmed_authors>Guo S</pubmed_authors><pubmed_authors>Zhao Y</pubmed_authors><pubmed_authors>Xu J</pubmed_authors></additional><is_claimable>false</is_claimable><name>A viral infection prediction model for patients with r/r B-cell malignancies after CAR-T therapy: a retrospective analysis.</name><description>&lt;h4>Background&lt;/h4>Chimeric antigen receptor T cell (CAR-T) therapy for relapsed/refractory (r/r) B cell acute lymphoblastic leukemia (B-ALL) and B cell non-Hodgkin lymphoma (B-NHL) patients has shown promising effects, but side effects such as viral infections have been observed.&lt;h4>Methods&lt;/h4>A total of 45 patients with r/r B-ALL and r/r B-NHL were included in this retrospective study. Patient demographics were recorded, with the primary endpoint being viral infection within 3 months post CAR-T treatment. Univariate and multivariate logistic regression analyses and least absolute shrinkage and selection operator (LASSO) regression analysis were used to analyze independent factors. The patients were divided into a training cohort of 28 and a validation cohort of 17 to construct a predict</description><dates><release>2025-01-01T00:00:00Z</release><publication>2025</publication><modification>2025-07-09T03:05:11.411Z</modification><creation>2025-07-09T03:05:11.411Z</creation></dates><accession>S-EPMC11968754</accession><cross_references><pubmed>40190552</pubmed><doi>10.3389/fonc.2025.1549809</doi></cross_references></HashMap>